Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7301 to 7350 of 8236 results

  1. Ovarian (epithelial), fallopian, peritoneal cancer - paclitaxel (encapsulated in XR-17 [ID565]

    Discontinued Reference number: GID-TA11209

    Technology appraisal guidance
    Discontinued

  2. Multiple myeloma (untreated) - carfilzomib (with melphalan and prednisone) [ID1133]

    Discontinued Reference number: GID-TA11210

    Technology appraisal guidance
    Discontinued

  3. Ibrutinib for treating relapsed or refractory follicular lymphoma and marginal zone lymphoma [ID977]

    Discontinued Reference number: GID-TA11238

    Technology appraisal guidance
    Discontinued

  4. Gefurulimab for treating antibody-positive generalised myasthenia gravis [TSID12256]

    In development Reference number: GID-TA11848 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. KRAS mutation testing of tumours in adults with metastatic colorectal cancer (discontinued)

    Discontinued Reference number: GID-DT14

    Diagnostics guidance
    Discontinued

  6. Intensity modulated radiotherapy for prostate cancer [ID17]

    Discontinued Reference number: GID-TAG396

    Technology appraisal guidance
    Discontinued

  7. Hernia

    Discontinued Reference number: GID-CGWAVE0771

    NICE guideline
    Discontinued

  8. Diagnostic services

    Discontinued Reference number: GID-CGWAVE0773

    NICE guideline
    Discontinued

  9. Workplace health for employees with disabilities and long-term conditions

    Discontinued Reference number: GID-PHG58

    NICE guideline
    Discontinued

  10. Community nursing care settings

    Discontinued Reference number: GID-SGWAVE0700

    Safe staffing guideline
    Discontinued

  11. Benralizumab to reduce exacerbations in moderate to very severe chronic obstructive pulmonary disease [ID1394]

    In development Reference number: GID-TA11808 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Inclacumab for preventing recurrent vaso-occlusive crises in sickle cell disease in people 16 years and over [ID6551]

    In development Reference number: GID-TA11690 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma [ID4044]

    In development Reference number: GID-TA10930 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Tiragolumab with atezolizumab for treating locally advanced unresectable stage 3 non-small-cell lung cancer after at least 2 cycles of platinum-based chemoradiation [ID6250]

    In development Reference number: GID-TA11278 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Baloxavir marboxil for reducing direct transmission of influenza A or B in people 5 to 64 years [ID6552]

    In development Reference number: GID-TA11646 Expected publication date: TBC

    Technology appraisal guidance
    In development

  16. Baloxavir marboxil for treating influenza in babies under 1 year [ID6555]

    In development Reference number: GID-TA11712 Expected publication date: TBC

    Technology appraisal guidance
    In development

  17. Neuro-Cells stem-cell treatment for traumatic spinal cord injury [ID6588]

    In development Reference number: GID-TA11629 Expected publication date: TBC

    Technology appraisal guidance
    In development

  18. Sacituzumab govitecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor [ID6375]

    In development Reference number: GID-TA11441 Expected publication date: TBC

    Technology appraisal guidance
    In development

  19. Etripamil for treating paroxysmal supraventricular tachycardia [ID6581]

    In development Reference number: GID-TA11750 Expected publication date: TBC

    Technology appraisal guidance
    In development

  20. Patritumab deruxtecan for treating EGFR mutation-positive advanced non-small-cell lung cancer after 1 or 2 tyrosine kinase inhibitor treatment [ID6467]

    In development Reference number: GID-TA11585 Expected publication date: TBC

    Technology appraisal guidance
    In development

  21. Lung transplantation with ex-vivo perfusion

    Discontinued Reference number: GID-IP1046

    Interventional procedures guidance
    Discontinued

  22. Epiduroscopic lumbar discectomy via the sacral hiatus for sciatica

    Discontinued Reference number: GID-IP2806

    Interventional procedures guidance
    Discontinued

  23. Optical Coherence Tomography to guide percutaneous coronary intervention

    In development Reference number: GID-IPG10394 Expected publication date: TBC

    Interventional procedures guidance
    In development

  24. Ex utero intrapartum therapy for fetal obstruction

    Discontinued Reference number: GID-IP1156

    Interventional procedures guidance
    Discontinued

  25. Superior rectal artery embolisation for haemorrhoids

    Discontinued Reference number: GID-IPG10417

    Interventional procedures guidance
    Discontinued

  26. Sunitinib in combination with a taxane for the first line treatment of advanced and/or metastatic breast cancer [ID58]

    Discontinued Reference number: GID-TAG391

    Technology appraisal guidance
    Discontinued

  27. Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use) [ID18]

    Discontinued Reference number: GID-TAG393

    Technology appraisal guidance
    Discontinued

  28. Pancreatic cancer - capecitabine [ID389]

    Discontinued Reference number: GID-TAG394

    Technology appraisal guidance
    Discontinued

  29. Cetuximab for the treatment of advanced non-small-cell lung cancer [ID9]

    Discontinued Reference number: GID-TAG395

    Technology appraisal guidance
    Discontinued

  30. Intensity modulated radiotherapy for head and neck cancer [ID15]

    Discontinued Reference number: GID-TAG397

    Technology appraisal guidance
    Discontinued

  31. Pazopanib for the second line treatment of advanced and/or metastatic renal cell carcinoma [ID70]

    Discontinued Reference number: GID-TAG398

    Technology appraisal guidance
    Discontinued

  32. Dasatinib for the treatment of acute lymphoblastic leukaemia [ID386]

    Discontinued Reference number: GID-TAG399

    Technology appraisal guidance
    Discontinued

  33. Juvenile idiopathic arthritis - adalimumab [ID385]

    Discontinued Reference number: GID-TAG400

    Technology appraisal guidance
    Discontinued

  34. Temozolomide for the treatment of advanced and metastatic melanoma [ID316]

    Discontinued Reference number: GID-TAG401

    Technology appraisal guidance
    Discontinued

  35. Juvenile idiopathic arthritis - abatacept [ID27]

    Discontinued Reference number: GID-TAG402

    Technology appraisal guidance
    Discontinued

  36. Breast cancer (locally advanced or metastatic) - ixabepilone [ID377]

    Discontinued Reference number: GID-TAG403

    Technology appraisal guidance
    Discontinued

  37. Lapatinib for breast cancer (first line use in advanced or metastatic hormone-sensitive breast cancer) [ID115]

    Discontinued Reference number: GID-TAG404

    Technology appraisal guidance
    Discontinued

  38. Vandetanib for the second line treatment of non-small cell lung cancer [ID46]

    Discontinued Reference number: GID-TAG405

    Technology appraisal guidance
    Discontinued

  39. Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]

    In development Reference number: GID-TAG406 Expected publication date: TBC

    Technology appraisal guidance
    In development

  40. Contusugene ladenovec for the treatment of recurrent unresectable squamous cell carcinoma of the head and neck [ID76]

    Discontinued Reference number: GID-TAG407

    Technology appraisal guidance
    Discontinued

  41. Nilotinib for the first line treatment of chronic myeloid leukaemia [ID79]

    Discontinued Reference number: GID-TAG408

    Technology appraisal guidance
    Discontinued

  42. Bone loss (therapy-induced) in non-metastatic breast cancer - denosumab [ID83]

    Discontinued Reference number: GID-TAG411

    Technology appraisal guidance
    Discontinued

  43. Psoriasis - briakinumab (suspended) [ID65]

    Discontinued Reference number: GID-TAG412

    Technology appraisal guidance
    Discontinued

  44. Bevacizumab for the treatment of recurrent glioblastoma multiforme [ID80]

    Discontinued Reference number: GID-TAG413

    Technology appraisal guidance
    Discontinued

  45. Hepatitis B (adults) - entecavir and tenofovir disoproxil fumarate [ID111]

    Discontinued Reference number: GID-TAG414

    Technology appraisal guidance
    Discontinued

  46. Interferon beta-1b, interferon beta-1a and glatiramer acetate for the treatment of single demyelinating event with clinically isolated syndrome [ID109]

    Discontinued Reference number: GID-TAG415

    Technology appraisal guidance
    Discontinued

  47. Atrial fibrillation - clopidogrel (in combination with aspirin) [ID95]

    Discontinued Reference number: GID-TAG416

    Technology appraisal guidance
    Discontinued

  48. Breast cancer (metastatic) -trastuzumab (as monotherapy and in combination with a taxane) [ID345]

    Discontinued Reference number: GID-TAG417

    Technology appraisal guidance
    Discontinued

  49. Rituximab for the treatment of rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs [ID333]

    Discontinued Reference number: GID-TAG418

    Technology appraisal guidance
    Discontinued

  50. Venous thromboembolism - apixaban (acute medical illness) [ID310]

    Discontinued Reference number: GID-TAG419

    Technology appraisal guidance
    Discontinued